secwatch.observer — SEC 8-K summary
======================================

Issuer:     2seventy bio, Inc. (—)
CIK:        0001860782
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001860782-23-000101
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

2seventy bio cuts workforce 40%, CEO to step down, Abecma revenue guidance lowered
--------------------------------------------------------------------------------

- Workforce reduction of ~40% (176 roles); expects $130M+ savings in 2024-2025 and $9M one-time costs; cash runway into at least 2026.
- CEO Nick Leschly to resign upon successor identification; plans to become Chairman. CFO Chip Baird promoted to COO.
- FY2023 Abecma U.S. revenue expected below prior $470-$570M guidance due to Q3 decline.
- bbT369 Phase I continues; SC-DARIC33 on clinical hold; two new programs (MUC-16, MAGE-A4 TCR) approaching IND in 2023.
- Expanded JW Therapeutics collaboration to include solid tumor and autoimmune CAR T programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/0001860782-23-000101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860782/000186078223000101/tvst-20230908.htm
  HTML page:      https://secwatch.observer/filing/0001860782-23-000101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer